Combined use of ABT-737 and the dual specificity PI3K/mTOR inhibitor PI-103 led to loss of c-Myc expression and apoptosis of Burkitt's lymphoma cells, whose tumorigenicity is driven by overexpression of the c-Myc gene [37]. This evidence concerns the gene MYC and Burkitt lymphoma.